Clinical trials: Diabetic Macular Edema
Diabetic Macular Edema
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KESTREL (NCT03481634)
- Testing
- Brolucizumab, Aflibercept
- Where
- 116 sites in United States, Argentina and 12 more
- Volunteers
- 566 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Age-related Macular Degeneration
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
This is a Phase 1/2, open-label, dose-escalation clinical study, enrolling 21 subjects in one of the two treatment groups to determine the effects of topical ocular administration of low dose or high dose MTP-131 given twice a…
- Trial name
- SPIOC-101 (NCT02314299)
- Testing
- MTP-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stealth BioTherapeutics Inc.
Diabetic Macular Edema
A Study to Evaluate the Safety and Tolerability of EXN407
This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved…
- Trial name
- NCT04565756
- Testing
- EXN407
- Where
- 11 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Exonate Limited
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Diabetic Macular Edema
The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)
Observe the safety and tolerability of the single and multiple doses of 601 in DME patients; study the pharmacokinetic characteristics of single and multiple doses of 601, Observe the Preliminary efficacy of 601 multiple…
- Trial name
- NCT04151407
- Testing
- Drug 601
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Diabetic Macular Edema (DME)
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18…
- Trial name
- CONGO (NCT04697758)
- Testing
- AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period…
- Conditions
- Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy, Center-involved Diabetic Macular Edema
- Trial name
- NCT06599684
- Testing
- INV-102
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Invirsa, Inc.
Diabetic Macular Edema
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin will reduce the occurrence of sustained moderate visual loss (SMVL) in patients with clinically significant macular edema.
- Trial name
- NCT00133952
- Testing
- Ruboxistaurin
- Where
- 41 sites in United States, Canada and 8 more
- Volunteers
- 309 people
- Sponsor
- Chromaderm, Inc.
Diabetic Macular Edema
Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)
This study will evaluate the efficacy of Ozurdex® as prescribed in clinical practice in France for the treatment of Diabetic Macular Edema (DME).
- Trial name
- Louvre 3 (NCT03003416)
- Testing
- dexamethasone intravitreal implant
- Where
- 25 sites in France
- Volunteers
- 115 people
- Sponsor
- Allergan
Diabetic Retinopathy
Multicenter Diagnostic Clinical Performance Study For Automated Detection of Diabetic Retinopathy
This study is a retrospective study to assess the efficacy and accuracy of the EyeCheckup software in screening for diabetic retinopathy in healthcare settings.
- Trial name
- NCT05471986
- Testing
- Color Fundus Photography/Non-Mydriatic Opthalmic Cameras
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Diabetic Macular Edema
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
This was a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.
- Trial name
- NCT05526729
- Testing
- Beovu
- Where
- 76 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Refractory Diabetic Macular Edema
A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from refractory diabetic macular edema.
- Trial name
- NCT04005430
- Testing
- Episcleral Dexamethasone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Targeted Therapy Technologies, LLC
Diabetic Retinopathy
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.
- Trial name
- NCT00090519
- Testing
- ruboxistaurin
- Where
- 84 sites in United States, Australia and 15 more
- Volunteers
- 731 people
- Sponsor
- Chromaderm, Inc.
Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD)
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings.
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment
- Trial name
- SPECTRUM-US (NCT06398080)
- Testing
- aflibercept 8 mg
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
This was a Phase III, randomized, double-masked, multi-center, active-controlled, two-arm study designed to evaluate the efficacy and safety of brolucizumab 6 mg compared to the active control, aflibercept 2 mg used per…
- Trial name
- KITE (NCT03481660)
- Testing
- Brolucizumab, Aflibercept
- Where
- 78 sites in Belgium, Bulgaria and 21 more
- Volunteers
- 360 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
- Trial name
- JADE (NCT07484074)
- Testing
- Faricimab, OLN324
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections.
- Trial name
- NCT00040313
- Testing
- pegaptanib sodium (Macugen)
- Sponsor
- Eyetech Pharmaceuticals
Diabetic Macular Edema
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation at various doses in patients with diabetic macular edema.
- Trial name
- NCT00656643
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Santen Inc.
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705555
- Testing
- MK-8748, Aflibercept
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment…
- Trial name
- RETAIN (NCT01171976)
- Testing
- Ranibizumab
- Where
- 68 sites in Belgium, Czechia and 11 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals